LABS score–a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: A single-center retrospective study

No widely used prognostic tool exists to demonstrate the benefit of oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX4) in patients with advanced hepatocellular carcinoma (HCC). We aimed to establish a prognostic score and demonstrate the real-world efficacy of FOLFOX4 chemotherapy in Thai patients.